Keyword: SGLT2s

8. Janumet

Janumet, which combines Merck’s own blockbuster DPP-4 drug Januvia with metformin, reeled in $984 million in U.S. sales in 2016.

7. Invokana

2016 wasn’t the easiest year for Invokana. For one, European regulators began scrutinizing the med over a potential link to toe amputations; in May, the FDA followed up with a black box warning citing an increased risk of leg and foot amputations.

Top 10 diabetes drugs by 2016 sales

Formulary exclusions, pricing, biosimilars and cardiovascular outcomes data have impacted the U.S. diabetes space. We’ve compiled last year’s U.S. sales rankings for you, along with some insight into what to expect for each of the top meds going forward.